by Lance Smith | Mar 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it is implementing an interim analysis of the Phase III...by Lance Smith | Mar 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Mitigating the Impact on Site Monitoring Efforts Due to Covid-19 KING OF PRUSSIA, PA, US – Mar 18, 2020 – CluePoints, the premier provider of Risk-Based Trial Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced that it...by Lance Smith | Mar 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program Guildford, UK – 30 March 2020: Ergomed plc (ERGO.L) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services...by Lance Smith | Mar 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
The COVID-19 pandemic continues to dominate the news and is likely to for quite some time. The biopharma industry is doing what it can to test and repurpose therapies, develop diagnostics and respond to the crisis. Also, although some clinical trials are being slowed...by Lance Smith | Mar 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Farxiga is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III...